User login
A supplement to Pediatric News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.
Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Target Audience
This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.
Copyright © 2007 Elsevier Inc.
A supplement to Pediatric News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.
Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Target Audience
This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.
Copyright © 2007 Elsevier Inc.
A supplement to Pediatric News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.
Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Target Audience
This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.
Copyright © 2007 Elsevier Inc.
